Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer
Phase 2
Active, not recruiting
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 69
- Registration Number
- NCT04544189
- Locations
- 🇨🇳
Novartis Investigative Site, Tianjin, China
Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection
- Conditions
- MelanomaAdjuvant
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT04544202
Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome
Phase 2
Active, not recruiting
- Conditions
- Sjogren's Syndrome
- Interventions
- Drug: CFZ533 (iscalimab)Other: CFZ533 Placebo
- First Posted Date
- 2020-09-09
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 206
- Registration Number
- NCT04541589
- Locations
- 🇺🇸
Tufts School of Dental Medicine, Boston, Massachusetts, United States
🇺🇸The John Hopkins Jerome L Greene Sjogren, Baltimore, Maryland, United States
🇺🇸Ochsner Health System Research Department, Baton Rouge, Louisiana, United States
Managed Access Program (MAP) for Patients Diagnosed With Secondary Progressive Multiple Sclerosis With Active Disease
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT04540861
Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy
Phase 1
Completed
- Conditions
- Progressive Supranuclear Palsy (PSP)
- Interventions
- Drug: placebo
- First Posted Date
- 2020-09-04
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 59
- Registration Number
- NCT04539041
- Locations
- 🇺🇸
University of California San Diego, La Jolla, California, United States
🇺🇸Mayo Clinic Rochester, Rochester, Minnesota, United States
🇺🇸Vanderbilt University Medical CenterX, Nashville, Tennessee, United States
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer
Phase 2
Active, not recruiting
- Conditions
- Advanced Breast Cancer
- Interventions
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT04524000
- Locations
- 🇯🇵
Novartis Investigative Site, Niigata, Japan
Nilotinib, for Patients With CML-CP or CML-AP
- Conditions
- Chronic Myelogenous Leukemia (CML)
- First Posted Date
- 2020-08-19
- Last Posted Date
- 2023-04-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT04518644
Study of Efficacy and Safety of Voretigene Neparvovec in Japanese Patients With Biallelic RPE65 Mutation-associated Retinal Dystrophy
Phase 3
Active, not recruiting
- Conditions
- Biallelic RPE65 Mutation-associated Retinal Dystrophy
- Interventions
- Genetic: voretigene neparvovec
- First Posted Date
- 2020-08-18
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 4
- Registration Number
- NCT04516369
- Locations
- 🇯🇵
Novartis Investigative Site, Meguro-ku, Tokyo, Japan
Study of Mechanism of Action of Ligelizumab (QGE031) in Patients With Chronic Urticaria
Phase 1
Terminated
- Conditions
- Chronic Spontaneous UrticariaCholinergic UrticariaCold Urticaria
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-08-14
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 11
- Registration Number
- NCT04513548
- Locations
- 🇩🇪
Novartis Investigative Site, Berlin, Germany
Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer
- Conditions
- Small Cell Lung Carcinoma
- First Posted Date
- 2020-08-11
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT04507919
© Copyright 2025. All Rights Reserved by MedPath